Half Year Results Presentation

ü 1H FY26 Revenue up 53% or $2.8M to $8.0M from 1H FY25 ü 1H FY26 Normalised EBITDA of $1.6M at 20% operating margin ü Profit after tax of $1.5 million (1H FY25: $1.0 million loss) ü Positive operating cashflow ü Major global pharma clinical trial execution progressing as planned ü TrialsWest clinic network expansion progressing ahead of expectations ü SaMD order and bid (but not awarded) pipeline